Reducing phaco-induced apoptosis

Article

Cell apoptosis caused by free-radical formation during phacoemulsification can be mediated by the introduction of ascorbic acid, according to a study published in the December 2008 issue of the Journal of Cataract & Refractive Surgery.

Cell apoptosis caused by free-radical formation during phacoemulsification can be mediated by the introduction of ascorbic acid, according to a study published in the December 2008 issue of the Journal of Cataract & Refractive Surgery.

Naphtali Savion, PhD of Tel-Aviv University, Israel and colleagues assessed cell apoptosis in bovine corneal endothelial cells (CECs), which were cultured on gas-permeable flexible membranes, and then exposed to phacoemulsification. As a control, the researchers also examined cell apoptosis in CECs exposed to hydrogen peroxide for a period of 48 hours.

The researchers found that cell apoptosis increased from 45±12 apoptic nuclei per square millimetre before phacoemulsification to 334±29 48 hours postoperatively. Following 48 hours' exposure to hydrogen peroxide, apoptosis was 345±6 (H2O2 concentration, 50 µM) and 376±1 (H2O2 concentration, 100 µM). Adding ascorbic acid decreased the mean 48-hour post-phaco apoptosis level to 219±15 (ascorbic acid concentration, 1 mM) and 130±29 (ascorbic acid concentration, 10 mM), although applying shear forces up to 2000 seconds1 for 60 minutes did not alter the rate of apoptosis.

The researchers concluded that the increased rate of cell apoptosis that results from phacoemulsification is likely to be caused by free radical formation, and can therefore be modified through the application of ascorbic acid.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.